70-gene signature not cost-effective in breast cancer

70-gene signature not cost-effective in breast cancer
For patients with node-negative breast cancer, the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in the Journal of Clinical Oncology.

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in the Journal of Clinical Oncology.

Julia Bonastre, Ph.D., from Gustave Roussy in Villejuif, France, and colleagues conducted an economic analysis of the 70- used to guide adjuvant chemotherapy decision making in patients with NNBC. The 70-gene signature was compared with Adjuvant! Online and chemotherapy in all patients as a basis for the decision to administer adjuvant chemotherapy. Costs, life-years (LYs), and quality-adjusted life-years (QALYs) were compared over a 10-year period.

The researchers observed similar mean differences in LYs and QALYs for the three strategies. Higher cost was seen in association with the 70-gene strategy, with a mean difference of €2,037 and €657 compared with Adjuvant! Online and systematic chemotherapy, respectively. The probability of being the most cost-effective strategy was 92 percent for Adjuvant! Online, 6 percent for systematic chemotherapy, and 2 percent for the 70-gene signature, for a €50,000 per QALY willingness-to-pay threshold.

"Optimizing decision making based on the 70-gene signature is unlikely to be cost-effective in patients with NNBC," the authors write.


Explore further

Adjuvant therapy shows promise in biliary tract cancer

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Clinical Oncology

Copyright © 2014 HealthDay. All rights reserved.

Citation: 70-gene signature not cost-effective in breast cancer (2014, October 18) retrieved 11 April 2021 from https://medicalxpress.com/news/2014-10-gene-signature-cost-effective-breast-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments